PD-1/PD-L1 signaling has been shown to be pivotal in regulating immune dysfunction, particularly in conditions such as sepsis (10), the soluble forms of these molecules, sPD-1 and sPD-L1, have emerged as rapid immune biomarkers and have demonstrated utility in the diagnosis and risk stratification of various critical illnesses similar to severe pneumonia (SP) (11–14). Here, SPDL1 is linked to susceptibility to pneumonia measurement.